Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
Medscape11y
The Role of Ursodeoxycholic Acid in Non-alcoholic Steatohepatitis
Effective therapy for NASH is still lacking. In this study, we investigated the effects of Ursodeoxycholic acid (UDCA) in the treatment of NASH. Methods: Western and Chinese databases were ...
Nature1mon
What is the role of ursodeoxycholic acid in therapy for PSC?
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123 , 1238–1251 (2002). Article CAS PubMed Google Scholar ...
The Pharma Letter4d
Seladelpar wins conditional EC approval for rare liver disease
Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...
Here's why Shilpa Medicare share price jumped 8% in trade on February 13
The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...
India Infoline12d
Shilpa Medicare Gets CDSCO Nod for NAFLD Drug
The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...